Tacrolimus in pancreas transplantation: A multicenter analysis

Clinical Transplantation

Volumn 11, Issue 4, 1997, Pages 299-312

  Gruessner, Rainer W G ^a,o   Gruessner, A ^a   Drangstveit, M B ^a   Sutherland, D E R ^a   Egidi, F ^b   Corry, R ^b   Starzl, T ^b   Burke, G ^c   Stratta, R ^d   Marsh, C ^e   Perkins, J ^e   Sollinger, H ^f   Munda, R ^g   First, R ^g   Johnson, C ^h   Benedetti, E ⁱ   Kaufman, D ^j   Brayman, K ^k   Fabrega, A ^l   Martin, M ^l   Boudreaux, P ^m   Frey, D ^m   Stock, P ⁿ   Melzer, J ⁿ   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f St Luke's Sinai Samaritan Med C   (United States)

^g UNIVERSITY OF CINCINNATI   (United States)

^h MEDICAL COLLEGE OF WISCONSIN   (United States)

ⁱ UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY OF PENNSYLVANIA   (United States)

^l UNIVERSITY OF IOWA   (United States)

^m LOUISIANA STATE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

Immunosuppression; Pancreas transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; BONE MARROW TRANSPLANTATION; CASE-CONTROL STUDIES; CYCLOSPORINE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LYMPHOMA; MALE; MUROMONAB-CD3; MYCOPHENOLIC ACID; NERVOUS SYSTEM DISEASES; PANCREAS TRANSPLANTATION; PREDNISONE; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030812003     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. GRUESSNER RWG, BURKE GW, STRATTA R, et al. Multicenter analysis of the first experience with FK 506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61: 261.
2. SOLLINGER HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
3. SUTHERLAND DER, GRUESSNER A. Pancreas transplant results in the United Network for Organ Sharing (UNOS) United States of America (USA) Registry compared with non-USA data in the International Registry. In: TERASAKI PI, CECKA JM, eds. Clinical Transplants 1994. Los Angeles: UCLA Tissue Typing Laboratory, 1995; pp. 49-70.
4. BURKE GW, RICORDI C, KARATZAS T, et al. Donor bone marrow infusion in simultaneous pancreas/kidney transplant recipients: A preliminary study. Transpl Proc 1995: 27: 3121.
5. CORRY RJ, EGIDI MF, SHAPIRO R, et al. Simultaneous pancreas/kidney/bone marrow transplantation under FK 506 without anti-T-cell induction therapy. Presented at the 21st Annual Meeting of the American Society of Transplant Surgeons (ASTS). May 17-19, 1995; Chicago, IL.
6. GRUESSNER RWG, SUTHERLAND DER. Clinical diagnosis in pancreas allograft rejection. In: SOLEZ K, RACUSEN LC, BILLINGHAM ME, eds. Solid Organ Transplant Rejection: Mechanisms, Pathology and Diagnosis. Marcel Dekker, Inc. New York, 1996; pp. 455-499.